The FDA authorized a COVID-19 booster shot for certain immunocompromised patients after evidence indicated a weak immune response following the initial two-dose series.
The FDA authorized a COVID-19 booster shot for certain immunocompromised patients after evidence indicated a weak immune response following the initial two-dose series.
